Position in EXEL
as of Jun 30, 2026
· filed Jul 21, 2026
Position Value
$322,868
+$80,712 QoQ
Shares Held
5,934
+5.1% QoQ
Ownership
0.002%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#122
of 228 holders
Holding Since
Jun 2025
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026J.W. COLE ADVISORS, INC. holds $3,075,638 across 11 Biotechnology names. EXEL ranks #5 (10.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
1,414 | $702,376 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
958 | $597,351 | |
| 3 | RVMD |
Revolution Medicines, Inc.
|
2,722 | $509,776 | |
| 4 | ACAD |
Acadia Pharmaceuticals Inc
|
16,906 | $427,721 | |
| 5 | EXEL |
Exelixis, Inc.
This page
|
5,934 | $322,868 | |
| 6 | INCY |
Incyte Corp
|
2,210 | $250,525 | |
| 7 | VCEL |
Vericel Corp
|
4,700 | $209,103 | |
| 8 | CRBU |
Caribou Biosciences, Inc.
|
11,269 | $19,833 |
All Filings in EXEL
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $322,868 | 5,934 | Shares | Sole | 2026-07-21 | |
| 2026-03-31 | $242,156 | 5,646 | Shares | Sole | 2026-04-23 | |
| 2025-12-31 | $234,665 | 5,354 | Shares | Sole | 2026-02-11 | |
| 2025-09-30 | $207,532 | 5,025 | Shares | Sole | 2025-11-05 | |
| 2025-06-30 | $226,527 | 5,139 | Shares | Sole | 2025-08-12 | |
| No filing history on record for this holder in this stock. | ||||||